PDCD1 and head and neck squamous cell carcinoma: The response came early in 2016, when the CheckMate-141 study [23] on nivolumab, an immune-modulating antibody against programmed cell death protein-1 (PD-1), demonstrated an unprecedented survival gain in pre-treated patients with R/M-SCCHN.